Morgan Steven G, McMahon Meghan, Mitton Craig, Roughead Elizabeth, Kirk Ray, Kanavos Panos, Menon Devidas
University of British Columbia.
Health Aff (Millwood). 2006 Mar-Apr;25(2):337-47. doi: 10.1377/hlthaff.25.2.337.
Many countries have centralized the clinical and economic assessments necessary for evidence-based drug coverage policy. We analyze such processes in Australia, Canada, New Zealand, and the United Kingdom. These countries apply comparable approaches to the assessment and appraisal of evidence but apply the processes to different types of drugs and use the reviews within different decision-making contexts. Review processes applied to all medicines and clearly tied to coverage decisions appear to influence national drug use. Rigor of process and transparency of data and rationale are believed to be important for maximizing the impact and political acceptability of the processes.
许多国家已将基于证据的药物覆盖政策所需的临床和经济评估集中化。我们分析了澳大利亚、加拿大、新西兰和英国的此类流程。这些国家在证据评估和评价方面采用了类似的方法，但将这些流程应用于不同类型的药物，并在不同的决策背景下使用这些审查。适用于所有药物并与覆盖决策明确相关的审查流程似乎会影响国家药物使用情况。据信，流程的严格性以及数据和理由的透明度对于最大限度地提高这些流程的影响力和政治可接受性至关重要。
